Chronic Fatigue Syndrome Research Takes Leap Forward With NIH Funding
Research centers are collaborating on projects to find causes of disease; Ampligen, Rituxan and KPAX-002 are only drugs in clinical trials.
You may also be interested in...
Chronic fatigue drug received two FDA complete response letters, but company now agrees to additional study, new CEO says. Firm hopes Argentine approval also bodes well.
The two-day workshop on chronic fatigue syndrome/myalgic encephalomyelitis elicited extensive, detailed testimony from patients about their symptoms and current treatment that will inform FDA policy, but it also underscored the challenges of explaining FDA’s regulatory processes to the patient community.
System needs to be changed to enable US FDA to share COVID-19 application data and inspection reports with other regulatory authorities, stakeholders urge. Merck’s Julie Gerberding and former FDA Commissioner Hamburg criticize company announcement of data via press release prior to submission.